Comanche Biopharma secured $40 million in new capital to advance its experimental siRNA injectable intended as the potential first therapy for preeclampsia into human testing. The funding will support IND‑enabling studies and early clinical trials across multiple sites. The infusion de‑risks a program in a high‑unmet‑need obstetric indication and signals investor appetite for pregnancy‑focused RNA therapeutics, while placing emphasis on safety and dosing strategies for maternal–fetal applications.